Furugen, Ayako

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy (Shiba-Kyoritsu)

Position

Associate Professor (Non-tenured)

Career 【 Display / hide

  • 2013.04
    -
    2015.06

    Hokkaido University, Hokkaido University Hospital

  • 2015.07
    -
    2023.03

    Hokkaido University, Faculty of Pharmaceutical Sciences

  • 2024.04
    -
    Present

    Keio University, Faculty of Pharmacy, Associate Professor

  • 2024.05
    -
    Present

    北海道大学, 大学院薬学研究院, 招へい教員(客員准教授)

Academic Background 【 Display / hide

  • 2004.04
    -
    2008.03

    Hokkaido University, Faculty of Pharmaceutical Sciences, 総合薬学科

    University, Graduated

  • 2008.04
    -
    2010.03

    Hokkaido University, Graduate School of Life Science, 生命医薬科学コース 修士課程

    Graduate School, Completed, Master's course

  • 2010.04
    -
    2013.03

    Hokkaido University, Graduate School of Life Science, 生命医薬科学コース 博士課程

    Graduate School, Completed, Doctoral course

Licenses and Qualifications 【 Display / hide

  • 薬剤師免許, 2008.04

 

Research Areas 【 Display / hide

  • Life Science / Clinical pharmacy

 

Papers 【 Display / hide

  • Validated UPLC-MS/MS method for quantification of melatonin receptor agonists and dual orexin receptor antagonists in human plasma and breast milk: Application to quantify suvorexant and lemborexant in clinical samples

    Hina Ishikawa, Ayako Furugen, Ayako Nishimura, Takeshi Umazume, Shuhei Ishikawa, Ryoichi Aoyagi, Katsuya Narumi, Keisuke Okamoto, Yoh Takekuma, Mitsuru Sugawara, Masaki Kobayashi

    Journal of Pharmaceutical and Biomedical Analysis (Elsevier BV)  251   116432 - 116432 2024.12

    Research paper (scientific journal), Corresponding author, Accepted,  ISSN  0731-7085

  • Alteration in folate carrier expression via histone deacetylase inhibition in BeWo human placental choriocarcinoma cells.

    Yuki Miyazawa, Ayako Furugen, Ryoichi Aoyagi, Haruna Kosugi, Ayako Nishimura, Takeshi Umazume, Katsuya Narumi, Masaki Kobayashi

    Toxicology in vitro : an international journal published in association with BIBRA    105934 - 105934 2024.09

    Research paper (scientific journal), Corresponding author, Accepted

     View Summary

    Folates are essential nutrients for fetal development during pregnancy. Valproic acid (VPA), an inhibitor of histone deacetylases (HDACs), alters the expression of folate carriers in placental cells; however, the underlying mechanisms remain unclear. Here, we aimed to determine the profiles of folate carriers (folate receptor alpha [FOLR1], solute carrier [SLC]-19A1, and SLC46A1) after inhibition of HDACs, especially class I and IIa HDACs, using different inhibitors and gene knockdown tests. Quantitative polymerase chain reaction revealed that BeWo cells (a trophoblast model) expressed HDACs and folate carriers, similar to human placental villi. FOLR1 expression was upregulated by VPA, apicidin, and trichostatin A, but downregulated by MS-275 after 24 h treatment. VPA and apicidin upregulated the expression of SLC46A1. These inhibitors downregulated SLC19A1 expression. TMP269 (a class IIa inhibitor) did not affect folate carrier levels. HDAC1/2 knockdown upregulated FOLR1 and SLC46A1 levels, whereas HDAC1/3 knockdown downregulated FOLR1 levels. Our findings suggest that the pharmacological inhibition of class I HDACs alters the expression of folate carriers in BeWo cells. By contrast, HDAC inhibitors exert different regulatory effects on folate carriers. Moreover, HDAC1/2 inhibition may be a potential mechanism involved in altering FOLR1 and SLC46A1 levels.

  • Contribution of aldehyde oxidase to methotrexate-induced hepatotoxicity: In Vitro and pharmacoepidemiological approaches.

    Ayako Moriyama, Hinata Ueda, Katsuya Narumi, Shuho Asano, Ayako Furugen, Yoshitaka Saito, Masaki Kobayashi

    Expert opinion on drug metabolism & toxicology  2024.05

    Research paper (scientific journal), Accepted

     View Summary

    BACKGROUND: Methotrexate (MTX) is partially metabolized by aldehyde oxidase (AOX) in the liver and its clinical impact remains unclear. In this study, we aimed to demonstrate how AOX contributes to MTX-induced hepatotoxicity in vitro and clarify the relationship between concomitant AOX inhibitor use and MTX-associated liver injury development using the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: We assessed intracellular MTX accumulation and cytotoxicity using HepG2 cells. We used the FAERS database to detect reporting odds ratio (ROR)-based MTX-related hepatotoxicity event signals. RESULTS: AOX inhibition by AOX inhibitor raloxifene and siRNA increased the MTX accumulation in HepG2 cells and enhanced the MTX-induced cell viability reduction. In the FAERS analysis, the ROR for MTX-related hepatotoxicity increased with non-overlap of 95% confidence interval when co-administered with drugs with higher Imax, u (maximum unbound plasma concentration)/IC50 (half-maximal inhibitory concentration for inhibition of AOX) calculated based on reported pharmacokinetic data. CONCLUSION: AOX inhibition contributed to MTX accumulation in the liver, resulting in increased hepatotoxicity. Our study raises concerns regarding MTX-related hepatotoxicity when co-administered with drugs that possibly inhibit AOX activity at clinical concentrations.

  • Monocarboxylate Transporters 1 and 2 Are Responsible for L-Lactate Uptake in Differentiated Human Neuroblastoma SH-SY5Y Cells

    Tomoya Sakuma, Yuto Mukai, Atsushi Yamaguchi, Yudai Suganuma, Keisuke Okamoto, Ayako Furugen, Katsuya Narumi, Shuhei Ishikawa, Yoshitaka Saito, Masaki Kobayashi

    Biological and Pharmaceutical Bulletin (Pharmaceutical Society of Japan)  47 ( 4 ) 764 - 770 2024.04

    Research paper (scientific journal), Accepted,  ISSN  0918-6158

  • Breast milk concentrations of acetaminophen and diclofenac - unexpectedly high mammary transfer of the general-purpose drug acetaminophen.

    Ryo Tamaki, Kiwamu Noshiro, Ayako Furugen, Ayako Nishimura, Hiroshi Asano, Hidemichi Watari, Masaki Kobayashi, Takeshi Umazume

    BMC pregnancy and childbirth 24 ( 1 ) 90 - 90 2024.01

    Research paper (scientific journal), Accepted

     View Summary

    BACKGROUND: Breastfeeding is considered to be the most effective way of ensuring the health and survival of newborns. However, mammary transfer of drugs administered to mothers to breastfeeding infants remains a pressing concern. Acetaminophen and diclofenac sodium are widely prescribed analgesics for postpartum pain relief, but there have been few recent reports on the mammary transfer of these drugs, despite advances in analytic techniques. METHODS: We conducted a study on 20 postpartum mothers from August 2019-March 2020. Blood and milk samples from participants were analyzed using liquid chromatography-electrospray ionization tandem mass spectrometry within 24 hours after oral administration of acetaminophen and diclofenac sodium. The area under the concentration-time curve (AUC) was calculated from the concentration curve obtained by a naive pooled-data approach. RESULTS: For acetaminophen, AUC was 36,053 ng/mL.h and 37,768 ng/mL.h in plasma and breast milk, respectively, with a milk-to-plasma drug concentration ratio of 1.048. For diclofenac, the AUC was 0.227 ng/mL.h and 0.021 ng/mL.h, in plasma and breast milk, respectively, with a milk-to-plasma drug concentration ratio of 0.093. CONCLUSIONS: While diclofenac sodium showed low mammary transfer, acetaminophen showed a relatively high milk-to-plasma drug concentration ratio. Given recent studies suggesting potential connections between acetaminophen use during pregnancy and risks to developmental prognosis in children, we believe that adequate information regarding the fact that acetaminophen is easily transferred to breast milk should be provided to mothers.

display all >>

Reviews, Commentaries, etc. 【 Display / hide

  • メトトレキサート誘発性肝障害におけるアルデヒドオキシダーゼの寄与-基礎および薬剤疫学的アプローチによる検証-

    鳴海克哉, 森山綾子, 上田一奈太, 淺野秀峰, 古堅彩子, 小林正紀

    医療薬学フォーラム講演要旨集 31st 2023

    ISSN  1348-0863

  • 乳汁・血漿中lacosamideのUPLC/MS/MS定量法ならびに乳汁移行性評価への応用

    古堅彩子, 西村あや子, 馬詰武, 石川陽菜, 鳴海克哉, 小林正紀

    医療薬学フォーラム講演要旨集 31st 2023

    ISSN  1348-0863

  • 長時間作用型ベンゾジアゼピン(BZD)系薬のMilk/Plasma ratio(M/P比)およびRelative Infant Dose(RID)の算出

    西村あや子, 古堅彩子, 馬詰武, 北村聖花, 武隈洋, 菅原満, 菅原満, 小林正紀

    医療薬学フォーラム講演要旨集 31st 2023

    ISSN  1348-0863

  • 腹膜透析中に発症した焦点性てんかんに対してラコサミドを導入した小児例の経験

    植田 佑樹, 佐藤 泰征, 林 麻子, 上田 泰弘, 木村 修平, 後藤 健, 中久保 佐千子, 中島 翠, 江川 潔, 岡本 孝之, 白石 秀明, 古堅 彩子, 小林 正紀, 真部 淳

    てんかん研究 ((一社)日本てんかん学会)  40 ( 2 ) 467 - 467 2022.08

    ISSN  0912-0890

  • 歯科領域における経口第3世代セフェム系抗菌薬減少戦略の評価:中断時系列分析

    山神彰, 鳴海克哉, 齋藤佳敬, 古堅彩子, 今井俊吾, 北川善政, 大廣洋一, 高木諒, 武隈洋, 菅原満, 菅原満, 小林正紀, 小林正紀

    医療薬学フォーラム講演要旨集 30th 2022

    ISSN  1348-0863

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • トロホブラスト分化マーカーを指標とした薬剤による胎児毒性の新規評価法の開発

    2023.11
    -
    2024.06

    横山臨床薬理研究助成基金, 令和5年度研究助成(一般研究助成), Principal investigator

  • 胎盤幹細胞由来syncytiotrophoblastを用いた薬物の胎盤通過性評価とメカニズムの解明

    2023.08
    -
    2025.03

    日本学術振興会, 科学研究費助成事業, 研究活動スタート支援, No Setting

  • 女性におけるVitamin D 状態の評価と胎盤機能との関連性

    2022.07
    -
    2023.06

    公益財団法人 三島海雲記念財団 2022年度 学術研究奨励金, Principal investigator

  • 不眠に対するセルフメディケーションを見据えた睡眠薬の乳汁移行に関する研究

    2022.06
    -
    2023.03

    公益財団法人 一般用医薬品セルフメディケーション振興財団 令和4年度(2022年) 調査・研究助成, Principal investigator

  • 妊娠期酸化ストレス制御を指向した、抗酸化物質の胎盤移行および機能の多面的評価

    2022.06
    -
    2023.03

    一般財団法人 旗影会, 2022 年度 旗影会研究助成, Principal investigator

display all >>

Awards 【 Display / hide

  • 2024年度 日本薬学会賞女性薬学研究者奨励賞

    古堅 彩子, 2023

  • 2019年度 日本薬学会北海道支部 奨励賞 (医療系)

    古堅 彩子, 2019

  • 平成27 年度 Postdoctoral Award

    古堅 彩子, 2015, 日本医療薬学会

 

Courses Taught 【 Display / hide

  • RESEARCH FOR BACHELOR'S THESIS 1

    2024

  • PRIOR LEARNING FOR CLINICAL PRACTICE 5

    2024

  • PHARMACEUTICAL-ENGLISH SEMINAR

    2024

  • EARLY EXPOSURE TO HOSPITAL & COMMUNITY PHARMACY

    2024

  • COMMUNITY PHARMACY

    2024

 

Committee Experiences 【 Display / hide

  • 2023.06
    -
    2024.03

    北海道薬剤師会, 学術・情報委員会委員

  • 2022.07
    -
    Present

    日本薬学会医療薬科学部会, 若手世話人